• Assistant Professor, Duke-NUS Graduate Medical School
• Clinical Senior Lecturer, Yong Loo Lin School of Medicine
• Member, SGH Research Grant Review Committee
• Member, SingHealth Central Institutional Review Board
• Programme Lead, Medicine ACP Research Interest Group
  

• National Medical Research Council Transition Award (S$375k)
• Duke/Duke-NUS Collaborative Pilot Grant (S$100k)
• Khoo Pilot Award (S$30k)
• Kay Kendall Leukaemia Fund Junior Clinical Research Fellowship (£275k)

• Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, et al. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. Vol. 20, Molecular cancer. 2021. p. 134. 
• Sun Y, Gao Y, Chen J, Huang L, Deng P, Chen J, et al. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Lett. 2021 Sep;521:268–80. 
• Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021 Oct;81(19):4059-4075.e11. 
• Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng R-J, et al. Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Vol. 35, Leukemia. 2021. p. 1225. 
• Russell J, Collins A, Fowler A, Karanth M, Saha C, Docherty S, et al. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Ann Hematol. 2021 Apr;100(4):1049–58. 
• Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, et al. No association between ECSIT germline mutations and hemophagocytic  lymphohistiocytosis in natural killer/T-cell lymphoma. Vol. 106, Haematologica. 2021. p. 1737–9. 
• Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150. 
• Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34385415
• Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng R-J, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Vol. 34, Leukemia. 2020. p. 3413–9. 
• Lin G-W, Xu C, Chen K, Huang H-Q, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020 Feb;21(2):306–16. 
• Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, et al. The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Oct;59(10):2336–41. 
• Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, et al. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res. 2015 Jul;1(3):125–33. 
• Wang M, Escudero-Ibarz L, Moody S, Zeng N, Clipson A, Huang Y, et al. Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. J Mol Diagn. 2015 Sep;17(5):521–32. 
• Grigoropoulos NF, Petter R, Van ’t Veer MB, Scott MA, Follows GA. Leukaemia update. Part 2: managing patients with leukaemia in the community. BMJ. 2013 Apr;346:f1932. 
• Grigoropoulos NF, Petter R, Van ’t Veer MB, Scott MA, Follows GA. Leukaemia update. Part 1: diagnosis and management. BMJ. 2013 Mar;346:f1660. 
• Grigoropoulos NF, Mathur A. Stem cells in cardiac repair. Curr Opin Pharmacol. 2006 Apr;6(2):169–75. 
  

Site PI

• CHRONOS-4 trial of copanlisib in indolent B-cell lymphoma
• Co-investigator in clinical trials (2008 – present, selected): 
• CHRONOS-3 trial of copanlisib in indolent B-cell lymphoma
• Quantum-First trial of quizartinib in AML
• Phase II trial of the selective PI3 kinase α/β inhibitor BA80-6496
• GS-1101, Phase 2 trial of idelalisib in chronic lymphocytic leukaemia
• GOYA and GALLIUM phase III trials of obinutuzumab
• Mab-CUTE, phase 3 study of subcutaneous maintenance rituximab